INTERCEPT PHARMACEUTICALS, INC. Insider Trading for October 2015
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in INTERCEPT PHARMACEUTICALS, INC. for October 2015.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 30 2015 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | M | 21.50 | 1,250 | 26,875 | 3,999 | |
| Oct 30 2015 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | M | 21.50 | 1,250 | 26,875 | 9,892 | 8.6 K to 9.9 K (+14.46 %) |
| Oct 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 9.82 | 974 | 9,567 | 1,947 | |
| Oct 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Sell | S | 182.22 | 974 | 177,482 | 962 | 1.9 K to 962 (-50.31 %) |
| Oct 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 9.82 | 974 | 9,567 | 1,936 | 962 to 1.9 K (+101.25 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 0.00 | 1,298 | 0 | 1,298 | |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 8.67 | 1,000 | 8,667 | 6,940 | |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | A | 161.16 | 10,600 | 1,708,296 | 10,600 | |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 159.04 | 54 | 8,588 | 24,062 | 24.1 K to 24.1 K (-0.22 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 163.39 | 1,000 | 163,390 | 24,116 | 25.1 K to 24.1 K (-3.98 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 0.00 | 1,298 | 0 | 25,116 | 23.8 K to 25.1 K (+5.45 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 8.67 | 1,000 | 8,667 | 23,818 | 22.8 K to 23.8 K (+4.38 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Grant | A | 0.00 | 4,050 | 0 | 22,818 | 18.8 K to 22.8 K (+21.58 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 0.00 | 1,622 | 0 | 1,623 | |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | A | 161.16 | 13,100 | 2,111,196 | 13,100 | |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 159.04 | 858 | 136,456 | 29,159 | 30 K to 29.2 K (-2.86 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 163.39 | 282 | 46,076 | 30,017 | 30.3 K to 30 K (-0.93 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 0.00 | 1,622 | 0 | 30,299 | 28.7 K to 30.3 K (+5.66 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Grant | A | 0.00 | 5,150 | 0 | 28,677 | 23.5 K to 28.7 K (+21.89 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 0.00 | 649 | 0 | 649 | |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | A | 161.16 | 3,250 | 523,770 | 3,250 | |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 0.00 | 649 | 0 | 12,608 | 12 K to 12.6 K (+5.43 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Grant | A | 0.00 | 1,250 | 0 | 11,959 | 10.7 K to 12 K (+11.67 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 0.00 | 4,867 | 0 | 4,868 | |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | A | 161.16 | 32,550 | 5,245,758 | 32,550 | |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 159.04 | 167 | 26,560 | 526,814 | 527 K to 526.8 K (-0.03 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 0.00 | 4,867 | 0 | 526,981 | 522.1 K to 527 K (+0.93 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Grant | A | 0.00 | 15,100 | 0 | 522,114 | 507 K to 522.1 K (+2.98 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Option Exercise | A | 161.16 | 10,600 | 1,708,296 | 10,600 | |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | McMinn Rachel | Chief Strategy Offi ... | Grant | A | 0.00 | 4,050 | 0 | 8,343 | 4.3 K to 8.3 K (+94.34 %) |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | See Remarks | Option Exercise | A | 161.16 | 13,450 | 2,167,602 | 13,450 | |
| Oct 05 2015 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | See Remarks | Grant | A | 0.00 | 5,200 | 0 | 13,578 | 8.4 K to 13.6 K (+62.07 %) |